SCIEX summit Day three: Emerging trends in analytical science

Join us in October to hear first-hand how scientists and researchers from around the globe are driving innovation through analytical science—as they share insights on the latest trends, advanced workflows, and techniques that are helping to shape the future of food safety, environmental health, pharmaceutical and biopharmaceutical breakthroughs, and cutting-edge techniques in biomedical and omics research.

This year’s summit will spotlight:

• Future-focused solutions: Explore how next-generation technologies and approaches are redefining the boundaries of analytical capability.
• Advanced strategies: Dive into cutting-edge methodologies that are transforming laboratories across pharma, biotech, environmental, food, and clinical domains.
• Emerging trends: Gain foresight into trends driving the future of analytical science

Whether you're a scientist, researcher, or industry innovator, this is your moment to be part of the conversations. Secure your spot today and be among the first to access exclusive content, speaker announcements, and agenda previews. Be ready for what’s next in analytical excellence.

Day three: Emerging trends in analytical science

• Explore emerging trends in analytical science that are redefining industry standards, workflows, and unlocking new possibilities in food, environmental, bioanalysis, and biopharmaceutical labs.
• Explore how advancements in mass spectrometry support GLP environments while maintaining data integrity and regulatory readiness.
• Discover detection of over 900 routine contaminants in under 11 minutes.
• Confirmed speakers include: Lund University, BOKU University, Pharmaron, and Novo Nordisk.

Agenda-at-a-glance

Welcome and introduction to emerging trends in analytical science

• Ferran Sanchez (Senior Manager, Market Development and Product Marketing, SCIEX)

Human exposure to ultra short chain PFAS

• Christian Lindh (Associate Professor, Lund University)

Bioaccumulation of PFAS in the human body due to environmental exposure is a growing public health concern. Because PFAS are widespread in both the environment and everyday consumer products, there is an urgent need for quantitative tools that can accurately and precisely measure low levels of PFAS in biological fluids, helping to assess their bioaccumulation and overall effects on the human body. This presentation will showcase innovative approaches using LC-MS/MS to study human exposure to short chain PFAS which are common breakdown products of other larger PFAS used in products such as F-gases, fluoropolymers and pesticides.

Key takeaways from the presentation:

• Introduce robust and efficient LC-MS/MS methods to measure bio exposure of trifluoroacetic acid (TFA) and other ultra short PFAS in human urine and blood
• Evaluate the impact of short chain PFAS exposure on human health and track the short- and long-term biological responses from the human body
• Demonstrate how the deployment of these methods for high-throughput biomonitoring studies can help in determining the potential toxic effects of ultra short PFAS bioaccumulation associated with human exposure 

Challenges and efficiency gains: LC-MS/MS analysis of >900 mycotoxins, plant toxins, and secondary metabolites in only 11 minutes

• Lidija Kenjeric (Research Associate, BOKU University, Institute of Bioanalytics and Agro-Metabolomics, Department of Agricultural Sciences, Tulln, Austria)

Optimization of high-throughput LC-MS/MS workflows introduces significant efficiency gains for routine contaminant analysis. However, understanding the technical limitations of mass spectrometry platforms remains critical, as these can directly influence method performance, sensitivity, and reliability.

Key takeaways from the presentation:

• Evaluation of the instrumental platforms showed that technological advancements enhanced data quality and precision at very low concentrations, enabling lower limits of quantitation.
• MRM acquisition settings of 1 ms dwell, 2 ms pause, 5 ms settling time enabled efficient data collection while maintaining data quality, even when analyzing a large number of analytes within an 11-minute runtime.
• Throughput optimization enhances efficiency, enabling up to 22 tons of CO2 emission reduction per year while delivering measurable financial benefits for analytical laboratories.

Bridging science and service: advancing regulated bioanalysis with next-generation mass spectrometry

• Tharun Ponduru (Senior Bioanalytical Scientist, LC-MS/MS Regulated Bioanalysis, Pharmaron)

Next-generation mass spectrometry is transforming regulated bioanalysis by improving robustness, achieving pg/mL sensitivities, minimizing service disruptions, and enabling scalable, compliant workflows. This presentation explores how these advancements support GLP environments while maintaining data integrity and regulatory readiness.

Key takeaways from the presentation:

• Enhanced robustness and sensitivity: Delivers consistent, high-quality data across study durations and complex matrices, supporting FDA/EMA expectations for method validation and reproducibility. Achieve reliable quantitation down to low pg/mL levels, essential for early-phase and biomarker studies.
• Improved serviceability: Smarter diagnostics and reduced maintenance help ensure instrument uptime in compliance-driven environments.
• Scalable, compliant efficiency: Enables faster method deployment and higher throughput while maintaining audit-readiness and GLP compliance.

Bioanalysis of oligonucleotides using enhanced protein precipitation and LC-MS

• Afrand Kamali (Senior Scientist Research, ADME, Novo Nordisk)

Bioanalysis of siRNAs and ASOs is a key step in the oligonucleotide drug development. A new simple extraction method; EPP; for protein precipitation with help of amines is demonstrated here. combination with fast and qcurate LC-MS technology is shown here reaching high sensitivity and accuracy.

Charge variant analysis for complex therapeutics

• Anita P. Liu (Associate Principal Scientist - Biologics Mass Spec, Merck)

Charge variant profiling is vital for biotherapeutic development, as it tracks molecular attributes that impact drug safety and efficacy. However, analyzing complex biologic modalities like Fc fusion proteins poses challenges because of their heterogeneity, including extensive glycosylation and sialylation. This case study discusses the strength of online icIEF-UV/MS in identifying problematic acidic variants and post-translational modifications, enabling risk mitigation and a deeper mechanistic understanding of highly glycosylated therapeutics.

Key takeaways from the presentation:

• Online icIEF-UV/MS enables rapid and robust analysis of charge variants, even in highly heterogeneous proteins.
• Enzymatic treatments and optimized conditions improve resolution and help identify post-translational modifications and glycan-related variants.
• This approach is a valuable tool for accelerating biologics pipeline development and in-depth protein characterization.
• Rapid identification of PTMs enables risk mitigation in developing highly glycosylated therapeutics.

Q&A roundtable: emerging trends in analytical science

• Moderated by: Ferran Sanchez